Table 1.
(A) Description of BE cases and screening colonoscopy controls without BEa; (B) histological characteristics of BE cases and screening colonoscopy controls without BEb
| Characteristicsa | Cases | Controls | P valuec |
|---|---|---|---|
| (A) | |||
| Total sample size | 218 | 439 | |
| Age mean (s.d.) | 63.2 (5.7) | 62.4 (6.6) | 0.12 |
| % Males | 97.3 | 96.6 | 0.65 |
| % Black/African-American | 11.9 | 41.7 | <0.0001 |
| % Non-Hispanic White | 87.2 | 56.0 | <0.0001 |
| % Hispanic | 8.3 | 9.6 | 0.58 |
| % H. pylori | 16.1 | 33.3 | <0.0001 |
| % Obese | 51.4 | 47.8 | 0.39 |
| Mean total cigarette pack years | 29.2 | 22.4 | 0.0047 |
| GERD symptoms ≥1 per week | 35.8 | 20.1 | <0.0001 |
| % PPI use > 1 per week | 71.3 | 22.8 | <0.0001 |
| % H2-receptor antagonist > 1 per week | 10.5 | 5.5 | 0.03 |
| % PPI or H2-receptor antagonist > 1 per week | 75.7 | 27.8 | <0.0001 |
| Mean duration of weekly GERD symptoms (years) | 19.6 | 7.2 | <0.0001 |
| % At least weekly GERD symptoms or acid suppression therapy | 73.4 | 32.6 | <0.0001 |
| Mean NSAID intake per week in the past 1 year | 3.0 (1.9) | 3.2 (1.9) | 0.18 |
| (B) | |||
| H. pylori (%) | 16.1 | 33.3 | <0.0001 |
| Corpus atrophy (%) | 11.5 | 18.7 | 0.02 |
| Antral atrophy (%) | 10.6 | 18.2 | 0.02 |
| Overall gastric atrophy (%) | 18.4 | 28.7 | 0.0004 |
| Active corpus gastritis | |||
| Grade 1 (%) | 6.9 | 12.1 | 0.04 |
| Grade 2 (%) | 10.1 | 19.1 | 0.003 |
| Any active corpus gastritis (%) | 17.0 | 31.2 | <0.0001 |
| Active antral gastritis | |||
| Grade 1 (%) | 8.7 | 13.2 | 0.09 |
| Grade 2 (%) | 7.3 | 16.9 | 0.0008 |
| Any active antral gastritis (%) | 16.1 | 30.1 | 0.0001 |
| Chronic corpus gastritis | |||
| Grade 1 (%) | 20.6 | 34.6 | 0.0002 |
| Grade 2 (%) | 12.4 | 23.0 | 0.001 |
| Any chronic corpus gastritis (%) | 33.0 | 57.6 | <0.0001 |
| Chronic antral gastritis | |||
| Grade 1 (%) | 20.6 | 28.0 | 0.04 |
| Grade 2 (%) | 6.4 | 20.3 | <0.0001 |
| Any chronic antral gastritis (%) | 27.1 | 48.3 | <0.0001 |
| Any corpus gastritis | |||
| Grade 1 (%) | 3.2 | 5.2 | 0.24 |
| Grade 2 (%) | 14.7 | 27.1 | 0.0004 |
| Any grade (%) | 17.9 | 32.4 | <0.0001 |
| Any antral gastritis | |||
| Grade 1 (%) | 6.4 | 5.9 | 0.80 |
| Grade 2 (%) | 10.1 | 24.6 | <0.0001 |
| Any grade (%) | 16.5 | 30.5 | 0.0001 |
| Exclusive antral gastritis (%) | 6.4 | 5.5 | 0.62 |
| Any active gastritis (%) | 19.7 | 33.7 | 0.0002 |
| Any chronic gastritis (%) | 39.5 | 62.9 | <0.0001 |
BE, Barrett's esophagus; GERD, gastroesophageal reflux disease; NSAID, nonsteroidal anti-inflammatory drug; PPI, proton pump inhibitor.
a
Most exposure information came from questions regarding exposures 1+ year before endoscopy.
b
IM, intestinal metaplasia.
c
P value derived from χ2-tests.